FDA Approves Abraxis's Abraxane

Abraxane® is a chemotherapy drug indicated for the treatment of metastatic breast cancer, in particular patients for whom previous forms of chemotherapy treatment have proven unsuccessful.

Abraxane® is a solvent-free chemotherapy drug that may help reduce side effects normally associated with other solvent-based treatments, as well as to allow for higher drug dosages.
Abraxane® is administered via infusion. Treatments normally last around 30 minutes.

Abraxane (paclitaxel) is a cancer (antineoplastic) medication. Paclitaxel interferes with the growth of cancer cells and slows their growth and spread in the body.

Abraxane is used in the treatment breast cancer.

Abraxane is the brand name of a prescription injectable medication known as protein or albumin bound paclitaxel. Doctors prescribe Abraxane for use in breast cancer tumors that have not responded to other types of treatment or for breast cancer that has spread to other parts of the body.

Abraxane works by causing structures within cancerous cells to become stable or rigid instead of fluid. This prevents the cancer cells from replicating and leads to their eventual death.

FDA has approved Abraxane for the treatment of metastatic breast cancer. This drug is an improved version of Taxol, which is currently used for the treatment of metastatic breast cancer. This new drug is an improved version of Taxol. Abraxane is manufactured by American Pharma and is the first approval for the group of drugs called, protein-bound particle drugs. These drugs are free of toxic solvents which may cause problems with the administration of chemotherapy drugs. Abraxane, consisting only of albumin-bound paclitaxel nanoparticles, and is free of toxic solvents. Abraxane is an step forward in the treatment of breast cancer. The pivotal clinical trial that lead to the FDA approval has demonstrated that Abraxane had superior response rate when compared to Taxol in patients with metastatic breast cancer.